RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+0.75%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$911M
AUM Growth
+$911M
(-5%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9
Top Buys
| 1 |
UnitedHealth
UNH
|
$17.9M |
| 2 |
McKesson
MCK
|
$8.23M |
| 3 |
Cooper Companies
COO
|
$7.72M |
| 4 |
Abbott
ABT
|
$6.74M |
| 5 |
Cigna
CI
|
$5.72M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$32.2M |
| 2 |
Johnson & Johnson
JNJ
|
$17.7M |
| 3 |
Medtronic
MDT
|
$9.11M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$6.48M |
| 5 |
Pfizer
PFE
|
$6.46M |
Sector Composition
| 1 | Healthcare | 95.19% |
| 2 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
CVS Health
CVS
$93B
| $12.9M | 1.42% |
173,000
+2,000
| +1% | +$149K |
|
27
Apellis Pharmaceuticals
APLS
$3.51B
| $12.2M | 1.34% |
185,000
-15,000
| -8% | -$990K |
|
28
Natera
NTRA
$23B
| $11.8M | 1.29% |
217,000
+52,000
| +32% | +$2.82M |
|
29
BioNTech
BNTX
$24.1B
| $11.3M | 1.24% |
92,000
-17,000
| -16% | -$2.08M |
|
30
Danaher
DHR
$143B
| $11.2M | 1.23% |
45,000
-5,000
| -10% | -$1.25M |
|
31
Privia Health
PRVA
$2.84B
| $10.9M | 1.19% |
395,667
+25,667
| +7% | +$705K |
|
32
Outset Medical
OM
$245M
| $10.2M | 1.12% |
560,000
+200,000
| +56% | +$3.66M |
|
33
Inspire Medical Systems
INSP
$2.53B
| $9.14M | 1% |
38,392
-22,608
| -37% | -$5.38M |
|
|
SILK
34
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $8.61M | 0.95% |
221,255
+25,384
| +13% | +$988K |
|
|
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.33M | 0.91% |
41,000
| – | – |
|
|
MRTX
36
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.89M | 0.87% |
215,000
-85,000
| -28% | -$3.12M |
|
37
10x Genomics
TXG
$1.66B
| $7.81M | 0.86% |
150,000
+75,000
| +100% | +$3.9M |
|
|
38
Pfizer
PFE
$141B
| $7.67M | 0.84% |
190,000
-160,000
| -46% | -$6.46M |
|
39
Insulet
PODD
$24.2B
| $7.61M | 0.83% |
24,000
-5,000
| -17% | -$1.58M |
|
|
RVNC
40
DELISTED
Revance Therapeutics, Inc.
RVNC
| $7.16M | 0.79% |
230,000
-208,000
| -47% | -$6.48M |
|
41
Cytokinetics
CYTK
$5.98B
| $7.01M | 0.77% |
205,000
-11,322
| -5% | -$387K |
|
42
Dynavax Technologies
DVAX
$1.19B
| $7M | 0.77% |
725,000
-58,519
| -7% | -$565K |
|
43
Neurocrine Biosciences
NBIX
$13.5B
| $6.94M | 0.76% |
70,000
-15,000
| -18% | -$1.49M |
|
44
Xencor
XNCR
$594M
| $6.85M | 0.75% |
250,000
-44,076
| -15% | -$1.21M |
|
|
KRTX
45
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.67M | 0.73% |
37,000
+7,000
| +23% | +$1.26M |
|
|
ISEE
46
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.66M | 0.73% |
280,000
-150,000
| -35% | -$3.57M |
|
47
Veeva Systems
VEEV
$44.4B
| $6.63M | 0.73% |
37,000
+2,500
| +7% | +$448K |
|
48
Immunocore
IMCR
$1.78B
| $6.24M | 0.68% |
131,288
-18,712
| -12% | -$889K |
|
49
Alignment Healthcare
ALHC
$3.23B
| $6.23M | 0.68% |
1,000,000
+675,000
| +208% | +$4.21M |
|
50
Royalty Pharma
RPRX
$15.8B
| $5.99M | 0.66% |
165,000
-50,000
| -23% | -$1.82M |
|